Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine

References

• Barczak , P. , Kane , N. , Andrews , S. , Congdon , A.M. , Clay , J.C. and Betts , T. 1988 . Patterns of psychiatric morbidity in agenito-urinary clinic. A validation of the hospital anxiety depression scale (HAD) . The British Journal of Psychiatry , 152 : 698 – 700 .
   PubMed Web of Science ®Google Scholar
• Barreiro , P. , Soriano , V. , Blanco , F. , Casimiro , C. , de la Cruz , J.J. and Gonzalez-Lahoz , J. 2000 . Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy . AIDS , 14 : 807 – 812 .
   PubMed Web of Science ®Google Scholar
• Calza , L. , Manfredi , R. , Colangeli , V. , Tampellini , L. , Sebastiani , T. Pocaterra , D. 2005 . Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia . AIDS , 19 : 1051 – 1058 .
   PubMed Web of Science ®Google Scholar
• Carr , A. , Hudson , J. , Chuah , J. , Mallal , S. , Law , M. Hoy , J. 2001 . HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study . AIDS , 15 : 1811 – 1822 .
   PubMed Web of Science ®Google Scholar
• Carr , A. , Samaras , K. , Thorisdotir , A. , Kaufmann , G. , Chisholm , D. and Cooper , D. 1999 . Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study . Lancet , 353 : 2093 – 2099 .
   PubMed Web of Science ®Google Scholar
• Carrieri , M.P. , Leport , C. , Protopopesccu , C. , Cassuto , J.P. , Bouvet , E. Peyramond , D. 2006 . Factors associated with nonadherence to higly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase . Journal of AIDS , 32 : 38 – 47 .
   Google Scholar
• Carrieri , M.P. , Spire , B. , Durand , S. , Katlama , C. , Peyramond , D. François , C. 2003 . Health-related quality of life after 1 year of highly active antiretroviral therapy . Journal of AIDS , 41 : 477 – 485 .
   Google Scholar
• Cohen , J. 1988 . Statistical power analysis for the behavioral sciences , 2nd ed , Hillsdale , NJ : Lawrence Erlbaum .
   Google Scholar
• Duran , S. , Savès , M. , Spire , B. , Cailleton , V. , Sobel , A. Carrieri , P. 2001 . Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy . AIDS , 15 : 2441 – 2444 .
   PubMed Web of Science ®Google Scholar
• Fisac , C. , Fumero , E. , Crespo , M. , Roson , B. , Ferrer , E. Virgili , N. 2005 . Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine . AIDS , 19 : 917 – 925 .
   PubMed Web of Science ®Google Scholar
• Hsiung , P.C. , Fang , C.T. , Chang , Y.Y. , Chen , M.Y. and Wang , J.D. 2005 . Comparison of WHOQOL_Bref and SF-36 in patients with HIV infection . Quality of Life Research , 14 ( 1 ) : 141 – 150 .
   PubMed Web of Science ®Google Scholar
• Justice , A.C. , Holmes , W. , Gifford , A.L. , Rabeneck , L. , Zackin , R. Sinclair , G. 2001 . Development and validation of a self-completed HIV symptom index . Journal of Clinical Epidemiology , 54 : S77 – S90 .
   PubMed Web of Science ®Google Scholar
• Martinez , E. , Arnaiz , J.A. , Podzamczer , D. , Dalmau , D. , Ribera , E. Domingo , P. 2003 . Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection . The New England Journal of Medicine , 349 : 1036 – 1046 .
   PubMed Web of Science ®Google Scholar
• Negredo , E. , Cruz , L. , Paredes , R. , Ruiz , L. , Fumas , C.R. Bonjoch , A. 2002 . Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression . Clinical Infectious Diseases , 34 : 504 – 510 .
   PubMed Web of Science ®Google Scholar
• Nicholas , P.K. , Kirksey , M. , Corless , I.B. and Kemppainen , J. 2005 . Lipodystrophy and quality of life in HIV: Symptom management issues . Applied Nursing Research , 18 : 55 – 58 .
   PubMed Web of Science ®Google Scholar
• Palella , F.J. Jr , Delaney , K.M. , Moorman , A.C. , Loveless , M.O. , Fuhrer , J. Satten , G.A. 1998 . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection . The New England Journal of Medicine , 338 : 853 – 860 .
   PubMed Web of Science ®Google Scholar
• Préau , M. , Marcellin , F. , Carrieri , M.P. , Lert , F. , Obadia , Y. and Spire , B. 2007 . Health-related quality of life in French people living with HIV in 2003: Results from the national ANRS-EN12-VESPA Study . AIDS , 21 ( Suppl. 1 ) : S19 – S27 .
   PubMed Web of Science ®Google Scholar
• Ruiz , L. , Negredo , E. , Pere , D. , Paredes , R. , Esthert , F. Balague , M. 2001 . Antiretroviral treatment simplification with nevirapine in protease inhibitors experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study . Journal of AIDS , 27 : 229 – 236 .
   PubMed Web of Science ®Google Scholar
• Spire , B. , Marcellin , F. , Cohen-Codar , I. , Flandre , P. , Boué , F. Dellamonica , P. 2008 . Impact of Lopinavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: Results of the MONARK trial . Antiviral Therapy , 13 ( 4 ) : 591 – 599 .
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control and Prevention 1992 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults . MMWR Recommendations Reports 41 RR-17 1 19
   Google Scholar
• Van Walraven , C. , Mahon , J.L. , Moher , D. , Bohm , C. and Laupacis , A. 1999 . Surveying physicians to determine the minimal important difference: Implications for sample size calculation . Journal of Clinical Epidemiology , 52 ( 8 ) : 717 – 723 .
   PubMed Web of Science ®Google Scholar
• Ware , J.E. , Kosinski , M. , Turner-Bowker , D.M. and Gandek , B. 2005 . How to score version 2 of the SF-12 Health Survey (with a supplement documenting version1) , Boston , MA : QualityMetric Incorporated Lincoln, Rhode Island and Health Assessment Lab .
   Google Scholar
• The WHOQOL-HIV Group 2002 . WHOQOL-HIV instrument. Users manual. Scoring and coding for the WHOQOL-HIV instruments . Geneva , , Switzerland : Department of Mental Health and Substance Dependence, World Health Organization .
   Google Scholar
• Zigmond , A.S. and Snaith , R.P. 1983 . The hospital anxiety and depression scale . Acta Psychiatrica Scandinavica , 67 : 361 – 370 .
   PubMed Web of Science ®Google Scholar